PUMA BIOTECHNOLOGY, INC.
PBYIPuma Biotechnology is a publicly traded biopharmaceutical company (NASDAQ: PBYI) headquartered in Los Angeles, CA.
Drugs in Pipeline
10
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
8dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
PBYI Earnings Report
EPS Est: $0.08 | FQ end 2026-06 | Call: 2026-08-06 15:00:00
How PBYI's past catalysts played out
lapatinib
HER2+ Metastatic Breast Cancer (MBC)
Capecitabine
Breast Cancer
Neratinib
Advanced Breast Cancer
HKI-272
Carcinoma, Non-Small-Cell Lung
Loperamide
Early Stage HER2+ Breast Cancer
vinorelbine
Breast Cancer
Trastuzumab
Breast Cancer
Alisertib
Hormone Receptor Positive HER-2 Negative Breast Cancer
Temsirolimus
Breast Cancer
Paclitaxel
Advanced Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
lapatinib | Phase 3 | HER2+ Metastatic Breast Cancer (MBC) | - | - |
Capecitabine | Phase 3 | Breast Cancer | - | - |
Neratinib | Phase 3 | Advanced Breast Cancer | - | - |
HKI-272 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Loperamide | Phase 2 | Early Stage HER2+ Breast Cancer | - | |
vinorelbine | Phase 2 | Breast Cancer | - | |
Trastuzumab | Phase 2 | Breast Cancer | - | - |
Alisertib | Phase 2 | Hormone Receptor Positive HER-2 Negative Breast Cancer | - | - |
Temsirolimus | Phase 2 | Breast Cancer | - | Patent 2032 |
Paclitaxel | Phase 2 | Advanced Breast Cancer | - | Patent 2034 |
Breast Cancer
4 drugs in this indication
Advanced Breast Cancer
2 drugs in this indication
Early Stage HER2+ Breast Cancer
1 drug in this indication
HER2+ Metastatic Breast Cancer (MBC)
1 drug in this indication
Carcinoma, Non-Small-Cell Lung
1 drug in this indication
Hormone Receptor Positive HER-2 Negative Breast Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in PUMA BIOTECHNOLOGY, INC.'s drug pipeline?→
CatalystAlert tracks 10 drug candidates in PUMA BIOTECHNOLOGY, INC.'s (PBYI) pipeline across Phase 3, Phase 2. Its lead program is lapatinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PUMA BIOTECHNOLOGY, INC.'s next FDA catalyst?→
PUMA BIOTECHNOLOGY, INC.'s (PBYI) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PBYI biotech catalysts?→
Add PBYI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PUMA BIOTECHNOLOGY, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.